ACADIA Pharmaceuticals 2023 Annual Report

ACADIA Pharmaceuticals' 2023 annual report highlights record revenues of $726.4 million driven by successful commercial launches of NUPLAZID and DAYBUE, first-in-class treatments for Parkinson's disease psychosis and Rett syndrome respectively. The company achieved cash flow positivity and advanced a robust pipeline including Phase 3 studies for Prader-Willi syndrome and Alzheimer's disease psychosis.